{"schema_version":"secwatch.filing_event.v1","accession":"0000784199-25-000136","form_type":"8-K","ticker":"AORT","cik":"0000784199","company_name":"ARTIVION, INC.","filed_at":"2025-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.362950+00:00","generated_at":"2026-05-17T15:54:39.325567+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Artivion appoints Lance Berry as COO, retains CFO role; CMO Stanton to retire March 2026","bullets":["Lance Berry appointed COO effective Aug 11, 2025, while continuing as CFO and Treasurer.","Berry receives $540k salary, 70% bonus target, $2.25M equity grant target for 2026.","Marshall Stanton, SVP Clinical Research and CMO, to retire effective March 31, 2026.","Stanton will provide transition services for up to one year post-retirement; no disagreement involved."],"urls":{"canonical":"https://secwatch.observer/filing/0000784199-25-000136","json":"https://secwatch.observer/filing/0000784199-25-000136.json","markdown":"https://secwatch.observer/filing/0000784199-25-000136.md","text":"https://secwatch.observer/filing/0000784199-25-000136.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/784199/000078419925000136/0000784199-25-000136-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/784199/000078419925000136/aort-20250806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T15:54:39.325567+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}